Last reviewed · How we verify
Topotecan, dexamethasone, vincristine
Topotecan is a topoisomerase I inhibitor, vincristine is a vinca alkaloid that disrupts microtubule formation, and dexamethasone is a corticosteroid that suppresses inflammation and immune response.
Topotecan is a topoisomerase I inhibitor, vincristine is a vinca alkaloid that disrupts microtubule formation, and dexamethasone is a corticosteroid that suppresses inflammation and immune response. Used for Acute lymphoblastic leukemia, Small cell lung cancer, Ovarian cancer.
At a glance
| Generic name | Topotecan, dexamethasone, vincristine |
|---|---|
| Sponsor | St. Jude Children's Research Hospital |
| Drug class | Topoisomerase I inhibitor, Vinca alkaloid, Corticosteroid |
| Target | Topoisomerase I, Tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Topotecan works by inhibiting the enzyme topoisomerase I, which is involved in DNA replication and repair. Vincristine, on the other hand, binds to tubulin and prevents the formation of microtubules, which are essential for cell division. Dexamethasone, a synthetic corticosteroid, has anti-inflammatory and immunosuppressive properties, which can help reduce swelling and inflammation in the body.
Approved indications
- Acute lymphoblastic leukemia, Small cell lung cancer, Ovarian cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea
- Vomiting
Key clinical trials
- A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies (PHASE1)
- A Study of Children With Refractory or Relapsed ALL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: